Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

ClinicalTrials.gov ID: NCT00002806

Public ClinicalTrials.gov record NCT00002806. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of procarbazine, lomustine, and vincristine followed by radiation therapy in treating adults who have supratentorial glioma.

Study identification

NCT ID
NCT00002806
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
43 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 1996 (Type not available)
Primary completion
Jan 2003 (Actual)
Completion
Jul 2004 (Actual)
Last update posted
Jul 13, 2016

1996 – 2004

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
CCOP - Scottsdale Oncology Program Scottsdale Arizona 85259-5404 —
CCOP - Carle Cancer Center Urbana Illinois 61801 —
CCOP - Cedar Rapids Oncology Project Cedar Rapids Iowa 52403-1206 —
CCOP - Iowa Oncology Research Association Des Moines Iowa 50309-1016 —
Siouxland Hematology-Oncology Sioux City Iowa 51101-1733 —
CCOP - Wichita Wichita Kansas 67214-3882 —
CCOP - Ann Arbor Regional Ann Arbor Michigan 48106 —
CCOP - Duluth Duluth Minnesota 55805 —
Mayo Clinic Cancer Center Rochester Minnesota 55905 —
CCOP - Metro-Minnesota Saint Louis Park Minnesota 55416 —
Quain & Ramstad Clinic, P.C. Bismarck North Dakota 58501 —
CCOP - Merit Care Hospital Fargo North Dakota 58122 —
Altru Health Systems Grand Forks North Dakota 58201 —
CCOP - Toledo Community Hospital Oncology Program Toledo Ohio 43623-3456 —
CCOP - Geisinger Clinical and Medical Center Danville Pennsylvania 17822-2001 —
Rapid City Regional Hospital Rapid City South Dakota 57709 —
CCOP - Sioux Community Cancer Consortium Sioux Falls South Dakota 57105-1080 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00002806, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2016 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00002806 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →